ProTransit has successfully completed preliminary field trials of our Pro-NP nanoparticles loaded with Super Oxide Dismutase and Catalase and formulated into a nighttime serum. The results of the trial, performed under the direction of Principle Investigator Dr. John Joseph at Clinical Testing Center of Beverly Hills, California, showed marked improvement in three key facial features: wrinkles, age spots and skin surface texture. Results were encouraging enough to launch phase II of the study, scheduled to begin April of 2021 and will complete in August of 2021.
Recent Comments